Evidence map›Paper›PMID 40634321›Full record

ArticleCell death discovery2025

Rsk2 inhibition induces an aneuploid post-mitotic arrest of cell cycle progression in osteosarcoma cells.

Armelle Carreau, Christina Baldauf, Lena Warlich, Magdalena Weingartner, Laura Brylka, Michael Amling, Thorsten Schinke, Julia Luther

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Armelle CarreauDepartment of Osteology and Biomechanics, University Medical Center Hamburg-Eppendorf, Martinistraße 52, Hamburg, Germany. moliere.armelle@gmail.com.ORCID http://orcid.org/0009-0006-6216-829X
Christina BaldaufDepartment of Osteology and Biomechanics, University Medical Center Hamburg-Eppendorf, Martinistraße 52, Hamburg, Germany.
Lena WarlichDepartment of Osteology and Biomechanics, University Medical Center Hamburg-Eppendorf, Martinistraße 52, Hamburg, Germany.
Magdalena WeingartnerInstitute of Plant Sciences and Microbiology, University of Hamburg, Ohnhorststrasse 18, Hamburg, Germany.
Laura BrylkaDepartment of Osteology and Biomechanics, University Medical Center Hamburg-Eppendorf, Martinistraße 52, Hamburg, Germany.
Michael AmlingDepartment of Osteology and Biomechanics, University Medical Center Hamburg-Eppendorf, Martinistraße 52, Hamburg, Germany.
Thorsten Schinke *Department of Osteology and Biomechanics, University Medical Center Hamburg-Eppendorf, Martinistraße 52, Hamburg, Germany.
Julia Luther *Department of Osteology and Biomechanics, University Medical Center Hamburg-Eppendorf, Martinistraße 52, Hamburg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteosarcoma is the most common primary bone tumor, which is associated with a high mortality rate. The c-Fos transgenic mouse model has been described to spontaneously develop osteosarcoma, and the ribosomal S6 kinase 2 (Rsk2) was found to be essential for c-Fos-induced osteosarcoma formation in mice. By isolating and characterizing osteosarcoma cell lines from FosTg and FosTg;Rsk2

Identifiers

PMID40634321
PMCPMC12241552

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.